Who has been buying Ensol Bioscience stock?

2 distinct insiders have filed 10 disclosed insider purchases in Ensol Bioscience (140610), most recently on 2026-03-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Ensol Bioscience have?

Ensol Bioscience has 10 buy-side and 5 sell-side disclosures on record, covering ₩12.7B ($8.8M) in total reported value, spanning 2025-01-02 to 2026-03-19.

Where does StockDrifts get Ensol Bioscience insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Ensol Bioscience 140610

Company

엔솔바이오사이언스Ensol Bioscience

Insiders

Buys

Total Value

₩12.7B ($8.8M)

Avg Return

-3.45%

Last Filing

2026-03-19

Ensol Bioscience (140610) has 10 disclosed insider purchases and 5 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩12.7B ($8.8M) in reported transaction value. The earliest filing StockDrifts holds for Ensol Bioscience is dated 2025-01-02; the most recent is 2026-03-19. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -3.45%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-03-19	BUY	주식매수선택권	문은정 Eunjeong Moon	vice president	1.4K	-	-	-
2026-03-19	BUY	주식매수선택권	전남득 Jeon Nam-deuk	Managing Director	10.0K	-	-	-
2026-03-18	SELL	Market Sell	전남득 Jeon Nam-deuk	Managing Director	-100	-	-	-
2026-03-17	SELL	Market Sell	전남득 Jeon Nam-deuk	Managing Director	-5.4K	-	-	-
2026-03-16	SELL	Market Sell	전남득 Jeon Nam-deuk	Managing Director	-2.7K	-	-	-
2026-03-13	SELL	Market Sell	전남득 Jeon Nam-deuk	Managing Director	-956	-	-	-
2026-03-12	SELL	Market Sell	전남득 Jeon Nam-deuk	Managing Director	-800	-	-	-
2025-10-02	BUY	Market Buy	형인우 Hyung In-woo	-	10.0K	₩14,410	+3.4%	₩144M ($100K)
2025-10-01	BUY	Market Buy	형인우 Hyung In-woo	-	3.1K	₩14,240	+4.6%	₩44M ($31K)
2025-09-30	BUY	Market Buy	형인우 Hyung In-woo	-	2.0K	₩14,030	+6.2%	₩28M ($19K)
2025-09-29	BUY	Market Buy	형인우 Hyung In-woo	-	10.3K	₩14,310	+4.1%	₩147M ($102K)
2025-09-26	BUY	Market Buy	형인우 Hyung In-woo	-	9.1K	₩14,130	+5.5%	₩129M ($89K)
2025-09-25	BUY	Market Buy	형인우 Hyung In-woo	-	5.5K	₩14,050	+6.0%	₩77M ($54K)
2025-09-23	BUY	Market Buy	형인우 Hyung In-woo	-	25.0K	₩14,690	+1.4%	₩367M ($255K)
2025-08-06	BUY	Market Buy	형인우 Hyung In-woo	-	400.0K	₩18,250	-18.4%	₩7.3B ($5.1M)
2025-08-06	BUY	Market Buy	형인우 Hyung In-woo	-	50.0K	₩18,250	-18.4%	₩913M ($634K)
2025-07-18	BUY	제3자배정유상증자	형인우 Hyung In-woo	-	789.1K	₩31,300	-52.4%	₩24.7B ($17.2M)
2025-06-11	BUY	장외매수	형인우 Hyung In-woo	-	810.9K	₩29,350	-49.2%	₩23.8B ($16.5M)
2025-03-20	BUY	Market Buy	형인우 Hyung In-woo	-	169.3K	₩21,000	-29.1%	₩3.6B ($2.5M)
2025-01-31	BUY	유상신주취득	형인우 Hyung In-woo	-	1.2M	₩27,050	-44.9%	₩31.9B ($22.2M)
2025-01-02	BUY	장외매수	형인우 Hyung In-woo	-	550.1K	₩17,930	-16.9%	₩9.9B ($6.8M)
2025-01-02	BUY	장외매수	김해진 Kim Hae-jin	CEO	550.1K	₩17,930	-16.9%	₩9.9B ($6.8M)
2025-01-02	SELL	장외매도	김해진 Kim Hae-jin	CEO	-550.1K	₩17,930	+16.9%	₩9.9B ($6.8M)

Frequently asked questions

Who has been buying Ensol Bioscience stock?: 2 distinct insiders have filed 10 disclosed insider purchases in Ensol Bioscience (140610), most recently on 2026-03-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Ensol Bioscience have?: Ensol Bioscience has 10 buy-side and 5 sell-side disclosures on record, covering ₩12.7B ($8.8M) in total reported value, spanning 2025-01-02 to 2026-03-19.
Where does StockDrifts get Ensol Bioscience insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Ensol Bioscience. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.